Adjuvant radiotherapy in the treatment of invasive intraductal papillary mucinous neoplasm of the pancreas: An analysis of the surveillance, epidemiology, and end results registry

Annals of Surgical Oncology

Volumn 19, Issue 4, 2012, Pages 1316-1323

  Worni, Mathias ^a,b   Akushevich, Igor ^c   Gloor, Beat ^b   Scarborough, John ^a   Chino, Junzo P ^a   Jacobs, Danny O ^a   Hahn, Stephen M ^d   Clary, Bryan M ^a   Pietrobon, Ricardo ^a   Shah, Anand ^d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

^c DUKE UNIVERSITY   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER INVASION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; LYMPH NODE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PREDICTION; RETROSPECTIVE STUDY; SURVIVAL TIME; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION;

ADENOCARCINOMA, MUCINOUS; AGED; CARCINOMA, PANCREATIC DUCTAL; COHORT STUDIES; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; PANCREATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84862488011     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-2088-2     Document Type: Article

References (39)

1. Khan S, Sclabas G, Reid-Lombardo KM. Population-based epidemiology, risk factors and screening of intraductal papillary mucinous neoplasm patients. World J Gastrointest Surg. 2010; 2:314-8.
2. Riall TS, Stager VM, Nealon WH, et al. Incidence of additional primary cancers in patients with invasive intraductal papillary mucinous neoplasms and sporadic pancreatic adenocarcinomas. J Am Coll Surg. 2007;204:803-13; discussion 813-4.
3. Kloppel G SE, Longnecker DS, et al. Histological typing of tumours of the exocrine pancreas. In: World Health Organization international classification of tumors. Berlin: Springer; 1996.
4. Longnecker DS AG, Hruban RH, Klöppel G. Intraductal papillary-mucinous neoplasms of the pancreas. In: Hamilton SR, Aaltonen LA, editors. WHO classification of tumours. Lyon, France: IARC Press; 2000. p. 237-40.
5. D'Angelica M, Brennan MF, Suriawinata AA, et al. Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. Ann Surg. 2004;239: 400-8. (Pubitemid 38229071)
6. Maire F, Hammel P, Terris B, et al. Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma. Gut. 2002;51:717-22. (Pubitemid 35216862)
7. Nakagohri T, Kinoshita T, Konishi M, et al. Surgical outcome of intraductal papillary mucinous neoplasms of the pancreas. Ann Surg Oncol. 2007;14:3174-80. (Pubitemid 47594293)
8. Niedergethmann M, Grutzmann R, Hildenbrand R, et al. Outcome of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas (IPMN): a 10-year experience. World J Surg. 2008;32:2253-60.
9. Schnelldorfer T, Sarr MG, Nagorney DM, et al. Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas. Arch Surg. 2008;143:639-46; discussion 646.
10. Wada K, Kozarek RA, Traverso LW. Outcomes following resection of invasive and noninvasive intraductal papillary mucinous neoplasms of the pancreas. Am J Surg. 2005;189:632-6; discussion 637.
11. Yopp AC, Allen PJ. Prognosis of invasive intraductal papillary mucinous neoplasms of the pancreas. World J Gastrointest Surg. 2010;2:359-62.
12. Turrini O, Waters JA, Schnelldorfer T, et al. Invasive intraductal papillary mucinous neoplasm: predictors of survival and role of adjuvant therapy. HPB (Oxford). 2010;12:447-55.
13. Fujii H, Inagaki M, Kasai S, et al. Genetic progression and heterogeneity in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol. 1997;151:1447-54. (Pubitemid 27479775)
14. Wilentz RE, Hruban RH. Pathology of cancer of the pancreas. Surg Oncol Clin North Am. 1998;7:43-65. (Pubitemid 28108792)
15. Poultsides GA, Reddy S, Cameron JL, et al. Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas. Ann Surg. 2010;251:470-6.
16. Wasif N, Bentrem DJ, Farrell JJ, et al. Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes. Cancer. 2010;116:3369-77.
17. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer. 1987;59:2006-10.
18. Crane CH, Varadhachary G, Pisters PW, et al. Future chemoradiation strategies in pancreatic cancer. Semin Oncol. 2007;34: 335-46. (Pubitemid 47176616)
19. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120:899-903. (Pubitemid 15040883)
20. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999; 230:776-82; discussion 782-4.
21. McDade TP, Hill JS, Simons JP, et al. A national propensity-adjusted analysis of adjuvant radiotherapy in the treatment of resected pancreatic adenocarcinoma. Cancer. 2010;116:3257-66.
22. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358:1576-85. (Pubitemid 33101907)
23. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-10. (Pubitemid 38339364)
24. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544-73.
25. http://www.seer.cancer.gov. Accessed 10 Aug 2011.
26. http://seer.cancer.gov/seerstat/. Accessed 10 Aug 2011.
27. Tomlinson JS, Jain S, Bentrem DJ, et al. Accuracy of staging node-negative pancreas cancer: a potential quality measure. Arch Surg. 2007;142:767-73; discussion 773-4.
28. Greene FL PD, Fleming ID, et al. AJCC cancer staging handbook. Chicago, IL: Springer; 2002.
29. Artinyan A, Hellan M, Mojica-Manosa P, et al. Improved survival with adjuvant external-beam radiation therapy in lymph node-negative pancreatic cancer: a United States population-based assessment. Cancer. 2008;112:34-42.
30. Lund JL, Harlan LC, Yabroff KR, Warren JL. Should cause of death from the death certificate be used to examine cancer-specific survival? A study of patients with distant stage disease. Cancer Invest. 2010;28:758-64.
31. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:15.
32. Brookhart MA, Schneeweiss S, Rothman KJ, et al. Variable selection for propensity score models. Am J Epidemiol. 2006;163: 1149-56. (Pubitemid 43987579)
33. Chari ST, Yadav D, Smyrk TC, et al. Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology. 2002;123:1500-7. (Pubitemid 35231650)
34. Neoptolemos JP, Cunningham D, Friess H, et al. Adjuvant therapy in pancreatic cancer: historical and current perspectives. Ann Oncol Official J Eur Soc Med Oncol. 2003;14:675-92. (Pubitemid 36621766)
35. Miller RC, Iott MJ, Corsini MM. Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS symposium. Int J Radiat Oncol Biol, Phys. 2009;75:364-8.
36. Salvia R, Fernandez-del Castillo C, Bassi C, et al. Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg. 2004;239:678-85; discussion 685-7.
37. Sohn TA, Yeo CJ, Cameron JL, et al. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg. 2004;239:788-97; discussion 797-9.
38. Woo SM, Ryu JK, Lee SH, et al. Survival and prognosis of invasive intraductal papillary mucinous neoplasms of the pancreas: comparison with pancreatic ductal adenocarcinoma. Pancreas. 2008;36:50-5.
39. Yopp AC, Katabi N, Janakos M, et al. Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcinoma. Ann Surg. 2011.